drugset / Trial / NCT06639347
A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A2102 for injection with Antitumor Therapy in Advanced Urothelial Carcinoma. To explore the reasonable dosage of SHR-A2102 for Advanced Urothelial Carcinoma.
Timeline
- Start
- 2024-11-04
- Primary completion
- 2027-05-31
- Completion
- 2027-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SHR-A2102 | Other / unclassified | — | — |
| Background | Adebrelimab | Monoclonal antibody | — | — |
| Background | SHR-8068 | Monoclonal antibody | — | — |